LS-102

LS-102 is a selective E3 ubiquitin ligase synoviolin (Syvn1) inhibitor. LS-102 inhibits the autoubiquitination of synoviolin with an IC 50 of 35 μM. LS-102 has the potential for rheumatoid arthritis treatment. In Vitro LS-102 inhibits proliferation of RSCs with an IC 50 of 5.4 μM. ? LS-102 suppresses proliferation of rheumatoid synovial cells (RSCs) in a Syvn1-dependent manner. LS-102 suppresses polyubiquitination of target proteins of Syvn1, including nuclear factor erythroid 2-related factor 2 (NRF2), V247M α-sarcoglycan mutant, and PGC-1β. LS-102 inhibits E3 ligase activity of Synoviolin (Syvn1). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Rheumatoid synovial cells (RSCs) Concentration: 20, 40, 60 μM Incubation Time: 12 hours Result: Inhibited proliferation of RSCs with an IC 50 of 5.4 µM. In Vivo LS-102 (1.3-4 mg/kg; i.p.; daily for 4 weeks) reduces clinical severity scores in a CIA model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 7-week-old DBA/1 male mice (CIA model) Dosage: 1.3, 4.0 mg/kg Administration: I.p.; daily for 4 weeks Result: Reduced the clinical severity scores. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet